Background : Chronic myelogenous leukemia (CML) is characterised by the t(9;22)(q34;q11.2) which results in the formation of the BCR/ABL1 fusion gene. Occasionally, the t(9;22) may be associated with submicroscopic deletions of chromosomes 9 and/or 22 which appear to be associated with a worse prognosis. Three or four-way variant t(9;22) may also occur. All these changes as well as gain of the Philadelphia chromosome which represents disease progression can be detected by fluorescence in situ hybridization (FISH) analysis. FISH analysis at presentation is used to determine the number of cells with BCR/ABL1 fusion and establish whether the patterns are typical or atypical. Response to therapy can then be monitored by serial testing. Patients...
The study aimed to examine a rare case of Philadelphia (Ph)-negative chronic myeloid leukemia (CML) ...
The t(9;22)(q34;q11) is evident in more than 90% of patients with chronic myelocytic leukemia (CML) ...
The t(9;22)(q34;q11) is evident in more than 90% of patients with chronic myelocytic leukemia (CML) ...
Background : Chronic myelogenous leukemia (CML) is characterised by the t(9;22)(q34;q11.2) which res...
The Philadelphia chromosome (Ph) resulting from translocation t(9;22)(q34;q11) is observed in more t...
This study was aimed to verify the efficacy of home-made LSI bcr/abl ES probe for detection of bcr/a...
Background: To evaluate prognostic effect of submicroscopic deletions involving breakage and fusion ...
Background/Aims: New molecular cytogenetic tech-niques are increasingly applied as a routine investi...
Background/Aims: New molecular cytogenetic techniques are increasingly applied as a routine investig...
Fluorescence in situ hybridization (FISH) has become an important tool both for defining initial chr...
We carried out fluorescence in situ hybridization (FISH) studies on 18 Ph+ chronic myeloid leukemia ...
CONTEXT: Identification of Philadelphia chromosome or BCR/ABL gene rearrangement in chronic myeloid ...
We describe the application of fluorescence in situ hybridization (FISH) in a case of suspected chro...
Abstract Background Chronic myeloid leukaemia (CML) is a haematopoietic stem cell disorder, almost a...
Complex variant 9;22 translocations occur in a significant minority of chronic myelogenous leukaemia...
The study aimed to examine a rare case of Philadelphia (Ph)-negative chronic myeloid leukemia (CML) ...
The t(9;22)(q34;q11) is evident in more than 90% of patients with chronic myelocytic leukemia (CML) ...
The t(9;22)(q34;q11) is evident in more than 90% of patients with chronic myelocytic leukemia (CML) ...
Background : Chronic myelogenous leukemia (CML) is characterised by the t(9;22)(q34;q11.2) which res...
The Philadelphia chromosome (Ph) resulting from translocation t(9;22)(q34;q11) is observed in more t...
This study was aimed to verify the efficacy of home-made LSI bcr/abl ES probe for detection of bcr/a...
Background: To evaluate prognostic effect of submicroscopic deletions involving breakage and fusion ...
Background/Aims: New molecular cytogenetic tech-niques are increasingly applied as a routine investi...
Background/Aims: New molecular cytogenetic techniques are increasingly applied as a routine investig...
Fluorescence in situ hybridization (FISH) has become an important tool both for defining initial chr...
We carried out fluorescence in situ hybridization (FISH) studies on 18 Ph+ chronic myeloid leukemia ...
CONTEXT: Identification of Philadelphia chromosome or BCR/ABL gene rearrangement in chronic myeloid ...
We describe the application of fluorescence in situ hybridization (FISH) in a case of suspected chro...
Abstract Background Chronic myeloid leukaemia (CML) is a haematopoietic stem cell disorder, almost a...
Complex variant 9;22 translocations occur in a significant minority of chronic myelogenous leukaemia...
The study aimed to examine a rare case of Philadelphia (Ph)-negative chronic myeloid leukemia (CML) ...
The t(9;22)(q34;q11) is evident in more than 90% of patients with chronic myelocytic leukemia (CML) ...
The t(9;22)(q34;q11) is evident in more than 90% of patients with chronic myelocytic leukemia (CML) ...